CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Active JNJ Drug +1 moredrug
Likely dose
Active JNJ Drug 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02217527
NCT02217527Phase 2Completed
CompareCT.gov

Development of a Novel Therapeutic for Smoking Cessation

Chengappa, K.N. Roy, MD·interventional·Posted Aug 15, 2014·Updated Aug 15, 2018

In Brief

A Phase 2 clinical trial evaluating Active JNJ Drug and Placebo pill for Smoking Cessation. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The study will assess a novel active drug vs. placebo on ability to reduce smoking and aid cessation during a one-week "practice" quit period for each condition in smokers with a high interest in quitting (i.e. crossover design). Medication effects on reducing withdrawal and cognitive impairment will help assess the mechanism to support quit smoking attempts.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 15, 2014
Enrollment StartNov 1, 2014
Primary CompletionJul 1, 2017
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.9 years ago

Interventions

Active JNJ Drugdrug

200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.

Placebo pilldrug

Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.